HAS2 and colon adenocarcinoma: We used the entire dataset and COAD and READ subgroups to validate the CM-2 (HYAL-1 + N-Cadh) and CM-6 (HYAL-1 + N-Cadh + HAS-2 + SNAI1 + Slug + MMP-9) transcript signatures, as these signatures showed independent prognostic capabilities in predicting clinical outcomes in cohort-1 (Figure 1 and Figure 2; Table 1).